Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in pediatric heterozygous familial hypercholesterolemia
NL-OMON47734Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Evolocumab plus background lipid-lowering therapy with Placebo plus background lipid-lowering therapy (2 arms). Primary endpoint: Percent change from baseline to week 24 in LDL-C. Started Nov 2016; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON47734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47734.